US Stock MarketDetailed Quotes
CRIS Curis
- 4.4500
- +0.4200+10.42%
Close Nov 27 16:00 ET
- 4.4500
- 0.00000.00%
Post 20:01 ET
37.68MMarket Cap-572P/E (TTM)
4.7000High4.0100Low93.00KVolume4.0100Open4.0300Pre Close409.00KTurnover1.22%Turnover RatioLossP/E (Static)8.47MShares17.490052wk High-4.31P/B34.00MFloat Cap3.510052wk Low--Dividend TTM7.64MShs Float2725.0000Historical High--Div YieldTTM17.12%Amplitude3.5100Historical Low4.3970Avg Price1Lot Size
About Curis Company
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Company Profile
SymbolCRIS
Company NameCuris
Listing DateAug 1, 2000
Founded2000
CEOMr. James E. Dentzer
MarketNASDAQ
Employees49
Fiscal Year Ends12-31
AddressBuilding C,128 Spring Street,Suite 500
CityLexington
ProvinceMassachusetts
CountryUnited States of America
Zip Code02421
Phone1-617-503-6500
Websitehttp://www.curis.com
Company Executives
- Name
- Position
- Salary
- James E. Dentzer
- Director, President and Chief Executive Officer
- 1.66M
- Jonathan B. Zung, PhD
- Chief Development Officer
- 882.42K
- Diantha Duvall
- Chief Financial Officer and Principal Accounting Officer
- 1.01M
- Martyn D. Greenacre
- Chairman of the Board
- 158.70K
- Dr. Kenneth I. Kaitin,PhD
- Independent Director
- 126.20K
- Dr. Marc Rubin,M.D.
- Independent Director
- 123.70K
- Dr. John A. Hohneker, M.D.
- Independent Director
- 106.20K
- Dr. Anne E. Borgman, M.D.
- Independent Director
- 103.70K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
